
Caboxen is identified as a cabozantinib product presented in 20 mg and 80 mg strengths. Cabozantinib is an oral targeted anticancer medicine classified as a multi-targeted tyrosine kinase inhibitor (TKI).
It works by blocking several proteins involved in cancer-cell growth, survival, migration, and the development of new blood vessels. This activity makes cabozantinib an important treatment option for selected cancers under appropriate medical supervision.
Cabozantinib is a prescription medicine and should only be used according to the instructions of a qualified oncology professional.
1. What Is Caboxen?
Caboxen is identified on this website as a product containing cabozantinib.
Cabozantinib is designed to interfere with molecular signaling pathways that contribute to cancer development and progression.
Its pharmacological activity involves several receptor tyrosine kinases, including MET, VEGFR, AXL, RET, and KIT.
By inhibiting these targets, cabozantinib can interfere with biological processes that support tumor growth and blood-vessel formation.
The medicine is used in specific cancer-treatment settings depending on its formulation and applicable regulatory approval.
2. Caboxen Available Strengths
Caboxen is presented in the following strengths:
Caboxen 20 mg
Cabozantinib · 20 mg stated strength
Caboxen 80 mg
Cabozantinib · 80 mg stated strength
The appropriate strength must be determined by the prescribing oncologist. These strengths should not be interpreted as independent dosing recommendations.
The exact dosage form associated with each Caboxen strength must be confirmed from the original packaging.
3. Active Ingredient: Cabozantinib
Cabozantinib is a multi-targeted tyrosine kinase inhibitor used in selected cancer-treatment settings.
Tyrosine kinases are enzymes that regulate cellular communication, growth, survival, and other biological processes.
Certain cancers use abnormal signaling pathways to support tumor development.
Cabozantinib inhibits multiple receptor tyrosine kinases involved in these processes.
Important Molecular Targets
| Molecular target | Biological role |
|---|---|
| MET | Cell growth, survival, and migration |
| VEGFR1–3 | Blood-vessel formation |
| AXL | Cell survival and tumor progression |
| RET | Cellular signaling and development |
| KIT | Cell growth and survival |
Its multi-target mechanism allows cabozantinib to interfere with several cancer-related signaling pathways.
4. What Is Caboxen Used For?
Cabozantinib has established uses in several cancer-treatment settings. The approved indications depend on the dosage form and applicable regulatory authorization.
These include:
Renal Cell Carcinoma
Renal cell carcinoma is the most common type of kidney cancer.
Cabozantinib tablets are used in specified patients with advanced renal cell carcinoma. Treatment may involve cabozantinib alone or in combination with nivolumab.
Hepatocellular Carcinoma
Hepatocellular carcinoma is a primary cancer of the liver.
Cabozantinib tablets are used in certain patients who have previously received sorafenib.
Differentiated Thyroid Cancer
Cabozantinib tablets are indicated for eligible patients with locally advanced or metastatic differentiated thyroid cancer that has progressed after specified previous treatment and is radioactive iodine-refractory or unsuitable for radioactive iodine treatment.
Neuroendocrine Tumors
Cabozantinib tablets have an approved role in certain previously treated, unresectable, locally advanced, or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors.
Medullary Thyroid Cancer
A separate cabozantinib capsule formulation is indicated for progressive metastatic medullary thyroid cancer.
These indications describe established reference formulations and should not automatically be attributed to Caboxen without confirmation of its product-specific regulatory status.
5. How Does Caboxen Work?
Cabozantinib works by inhibiting several receptor tyrosine kinases involved in cancer-related signaling.
Its activity may interfere with:
- Tumor-associated blood-vessel formation.
- Cancer-cell survival.
- Cellular growth and migration.
- Tumor invasion.
- Signaling pathways involved in disease progression.
Inhibition of VEGFR
VEGF receptors participate in angiogenesis, the formation of new blood vessels.
Tumors may stimulate blood-vessel development to obtain oxygen and nutrients.
Cabozantinib inhibits VEGF receptor signaling, interfering with processes involved in tumor-associated angiogenesis.
Inhibition of MET
MET signaling is involved in cellular growth, survival, and movement.
Abnormal MET activity may contribute to cancer progression. Cabozantinib inhibits this pathway.
Inhibition of AXL
AXL is associated with cell survival, migration, and interactions between tumor cells and their surrounding environment.
Cabozantinib’s activity against AXL contributes to its multi-target pharmacological profile.
6. Benefits of Cabozantinib Treatment
When prescribed for an appropriate indication, cabozantinib may provide several therapeutic benefits.
Potential benefits include:
- Interference with cancer-related signaling pathways.
- Inhibition of selected growth-related proteins.
- Reduction of signaling involved in tumor angiogenesis.
- Potential control of disease progression.
- Use in selected advanced cancer settings.
- Availability as a single-agent or combination treatment in certain indications.
Treatment response varies between individuals. Cabozantinib does not guarantee cancer remission or cure.
7. Dosage and Administration
The appropriate cabozantinib dose depends on the cancer being treated, formulation, treatment regimen, and individual patient characteristics.
Reference regimens for established products include:
| Treatment setting | Reference regimen |
|---|---|
| Advanced RCC, tablet monotherapy | 60 mg once daily |
| Advanced RCC with nivolumab, tablet formulation | 40 mg once daily |
| Certain HCC treatment, tablets | 60 mg once daily |
| Certain DTC and NET treatment, tablets | 60 mg once daily |
| Progressive metastatic MTC, capsules | 140 mg once daily |
These are reference-product regimens, not dosing instructions for Caboxen.
Administration With Food
The fasting requirements differ between reference formulations:
- Tablets: At least 1 hour before food or at least 2 hours after food.
- Capsules: At least 2 hours after food and 1 hour before the next meal.
Cabozantinib tablets and capsules are not bioequivalent and should not be substituted for one another.
Patients must confirm their exact formulation and follow its applicable prescribing information.
8. Common Side Effects
Cabozantinib may cause several adverse reactions.
Commonly reported side effects include:
- Diarrhea.
- Fatigue.
- Nausea.
- Vomiting.
- Decreased appetite.
- Weight loss.
- High blood pressure.
- Hand-foot skin reactions.
- Mouth sores.
- Constipation.
- Abdominal discomfort.
- Changes in taste.
- Voice changes.
Patients should inform their healthcare professional if side effects persist or interfere with normal activities.
9. Serious Side Effects
Cabozantinib can also cause serious adverse reactions.
Important risks include:
- Severe bleeding.
- Gastrointestinal perforation.
- Fistula formation.
- Arterial and venous blood clots.
- Severe hypertension.
- Liver toxicity.
- Proteinuria.
- Impaired wound healing.
- Osteonecrosis of the jaw.
- Reversible posterior leukoencephalopathy syndrome.
- Harm to an unborn baby.
Severe abdominal pain, significant bleeding, chest pain, sudden breathing difficulty, or sudden neurological symptoms require urgent medical attention.
10. Important Precautions
Before taking cabozantinib, patients should discuss their medical history with their oncologist.
Important considerations include:
- Existing high blood pressure.
- Previous bleeding problems.
- Cardiovascular disease.
- History of blood clots.
- Liver impairment.
- Kidney impairment.
- Recent or planned surgery.
- Dental problems.
- Pregnancy.
- Breastfeeding.
- Other prescription medicines and supplements.
Regular medical monitoring is essential during treatment.
11. Drug Interactions
Cabozantinib is metabolized through the CYP3A4 pathway.
Strong CYP3A4 inhibitors may increase cabozantinib exposure, while strong CYP3A4 inducers may decrease exposure.
Patients should disclose all medicines and supplements they use.
Never start or discontinue another medicine without discussing possible interactions with a healthcare professional.
12. Who Should Avoid or Use Cabozantinib With Caution?
Cabozantinib may not be appropriate for every patient.
Specialist assessment is important for individuals with:
- Severe or uncontrolled hypertension.
- Recent significant bleeding.
- Active gastrointestinal complications.
- Serious cardiovascular disease.
- Recent thromboembolic events.
- Significant liver impairment.
- Pregnancy.
- Other conditions that may increase treatment risks.
The treating oncologist must evaluate the potential benefits and risks before prescribing treatment.
13. Monitoring During Treatment
Patients receiving cabozantinib may require regular monitoring.
Healthcare professionals may assess:
- Blood pressure.
- Liver function.
- Kidney function.
- Urine protein.
- Blood tests.
- Calcium levels.
- Thyroid function.
- Skin condition.
- Gastrointestinal symptoms.
- Dental health.
- Treatment response.
The frequency of monitoring depends on the treatment regimen and the patient’s medical condition.
14. Storage and Handling
Caboxen should be stored according to the instructions supplied with the verified product.
General precautions include:
- Keep the medicine in its original packaging.
- Follow the specified storage temperature.
- Protect it from excessive heat and moisture.
- Keep it away from children and pets.
- Do not use expired medicine.
- Do not use damaged or suspicious packaging.
15. Caboxen Product Information Summary
| Feature | Description |
|---|---|
| Product name | Caboxen |
| Active ingredient | Cabozantinib |
| Strengths presented | 20 mg and 80 mg |
| Drug category | Anticancer medicine |
| Pharmacological class | Tyrosine kinase inhibitor |
| Route | Oral |
| Dosage form | Requires confirmation |
| Manufacturer | Requires verification |
| Regulatory status | Requires verification |
| Prescription requirement | Prescription medicine |
16. Frequently Asked Questions About Caboxen
1. What is Caboxen?
Caboxen is identified as a cabozantinib product presented in 20 mg and 80 mg strengths.
2. What is the active ingredient in Caboxen?
The stated active ingredient is cabozantinib, a multi-targeted tyrosine kinase inhibitor.
3. What is Caboxen 20 mg used for?
Caboxen 20 mg is a presented product strength. Its appropriate clinical use depends on the confirmed formulation and the prescribing oncologist’s instructions.
4. What is Caboxen 80 mg used for?
Caboxen 80 mg is another presented product strength. The appropriate dose and treatment indication must be established by a qualified healthcare professional.
5. Is Caboxen a chemotherapy medicine?
Cabozantinib is classified as a targeted anticancer medicine rather than conventional cytotoxic chemotherapy.
6. How does Caboxen work?
Cabozantinib inhibits several receptor tyrosine kinases involved in cancer-cell signaling, survival, and tumor-associated blood-vessel formation.
7. Can Caboxen cure cancer?
Cabozantinib is not a guaranteed cancer cure. It may help control certain cancers in approved treatment settings.
8. What are the common side effects?
Commonly reported reactions include diarrhea, fatigue, nausea, reduced appetite, weight loss, hypertension, and hand-foot skin reactions.
9. Does Caboxen require a prescription?
Yes. Cabozantinib is a prescription anticancer medicine requiring qualified medical supervision.
10. Can Caboxen be taken with food?
Food restrictions depend on the dosage form. Tablet and capsule instructions differ and must be confirmed before use.
11. Can Caboxen be combined with other cancer medicines?
Cabozantinib is used in certain combination regimens, including with nivolumab for eligible patients with advanced renal cell carcinoma. Combination treatment must be prescribed by an oncologist.
12. How long should treatment continue?
Treatment duration depends on the cancer type, treatment response, adverse reactions, and the oncologist’s assessment.
Important Product Disclaimer
Caboxen is identified as a cabozantinib product in 20 mg and 80 mg strengths. Its exact dosage form, manufacturer, product-specific regulatory authorization, and official prescribing information require confirmation.
The approved indications and administration instructions of other cabozantinib products should not automatically be applied to Caboxen.